Compare · KPRX vs LLY
KPRX vs LLY
Side-by-side comparison of Kiora Pharmaceuticals Inc. (KPRX) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KPRX and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.11T, about 95265.7x KPRX ($11.7M).
- Over the past year, KPRX is down 17.8% and LLY is up 52.7% - LLY leads by 70.5 points.
- LLY has been more active in the news (11 items in the past 4 weeks vs 3 for KPRX).
- LLY has more recent analyst coverage (25 ratings vs 1 for KPRX).
- Company
- Kiora Pharmaceuticals Inc.
- Eli Lilly and Company
- Price
- $2.63+3.95%
- $1178.57+0.73%
- Market cap
- $11.7M
- $1.11T
- 1M return
- +3.34%
- +5.00%
- 1Y return
- -17.81%
- +52.71%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 3
- 11
- Recent ratings
- 1
- 25
Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals, Inc., an ophthalmic specialty pharmaceutical company, develops therapies for the treatment of eye diseases in the United States. Its pipeline includes KIO-101, a small molecule DHODH inhibitor that treats immunologic eye diseases; KIO-201, an eye drop that enhances ocular wound healing and protects the ocular surface; and KIO-301, a small molecule that has the potential to restore vision in patients with inherited or age related retinal degeneration. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is based in Salt Lake City, Utah.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest KPRX
- CFO Tosca Melissa covered exercise/tax liability with 911 shares, decreasing direct ownership by 3% to 26,064 units (SEC Form 4)
- President and CEO Strem Brian M. covered exercise/tax liability with 1,869 shares, decreasing direct ownership by 3% to 58,823 units (SEC Form 4)
- Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium
- Kiora Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model
- SEC Form 4 filed by Director Stengone Carmine N.
- SEC Form 4 filed by Director Shapiro Aron
- SEC Form 4 filed by Director Parsons Erin
- SEC Form 4 filed by Director Hollander David
- SEC Form 4 filed by Director Walters-Hoffert Lisa
Latest LLY
- Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
- Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
- Three Biotechs Deliver Catalysts to Watch
- A Nasdaq-Listed Regenerative Tissue Company Just Opened a Lab: The Next Step in Scaling a Platform Built for a NEW Aesthetics Opportunity
- Innovent Biologics and Lilly Enter into Commercialization Agreement for Verzenios® (abemaciclib) in Mainland China
- Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
- What Medicare Part D patients need to know about accessing Foundayo (orforglipron) and Zepbound (tirzepatide) for weight management
- Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
- SEC Form 11-K filed by Eli Lilly and Company
- Lilly declares third-quarter 2026 dividend